La vendita allo scoperto per Repligen dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Repligen. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Repligen (NASDAQ:RGEN) Azioni, Report sulle vendite allo scoperto

Repligen

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Corp

WIIM

RGEN

Repligen shares are trading lower. Evercore ISI Group initiated coverage on the stock with an In-Line rating.

In the latest quarter, 6 analysts provided ratings for Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.67, a high estimate of $205.00, and a low estimate of $155.00. Highlighting a 7.12% decrease, the current average has fallen from the previous average price target of $195.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302831_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Repligen's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$155.00</td>
<td>-</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Repligen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Repligen compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Repligen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Repligen's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RGEN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Repligen analyst ratings.</a>
<h2>All You Need to Know About Repligen</h2>
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
<h3>Repligen's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Repligen showcased positive performance, achieving a revenue growth rate of 0.56% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Repligen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -20.21% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Repligen's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.7%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Repligen's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Repligen's debt-to-equity ratio is below the industry average. With a ratio of 0.35, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Repligen: Insights From 6 Analyst Reviews

Evercore ISI Group analyst Daniel Markowitz initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a In-Line rating and announces Price Target of $155.

News

Price Target

Initiation

Evercore ISI Group Initiates Coverage On Repligen with In-Line Rating, Announces Price Target of $155

On Tuesday,&nbsp;Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) purchased 908 Devices Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.
The purchase consideration is a payment of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44105311/repligen-purchases-bioprocessing-analytics-portfolio-from-908-devices" rel="noreferrer noopener">$70 million in cash</a>. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for health and safety applications.
Adding these desktop assets complements and strengthens Repligen&#8217;s differentiated PAT portfolio, providing its biopharmaceutical and CDMO customers with insights to optimize development processes and improve manufacturing efficiencies.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44112098/evgo-stock-slides-after-q4-eps-sales-miss-estimates" rel="noreferrer noopener">EVgo Stock Slides After Q4 EPS &amp; Sales Miss Estimates</a>
Products acquired from 908 Devices include MAVERICK and MAVEN for real-time monitoring and control of critical bioprocess parameters; REBEL, an at-line cell culture media analyzer; and ZipChip, a high-resolution sample separation device used to characterize product quality attributes.
Concurrently, 908 Devices reported fourth-quarter sales of $18.82 million, up 31% year over year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $16.4 million</a>. The increase was driven by a 22% increase in handheld revenue and a 56% <a href="https://www.benzinga.com/pressreleases/25/03/b44105638/908-devices-announces-strategic-transformation-and-reports-fourth-quarter-and-full-year-2024-finan" target="_blank" rel="noreferrer noopener">increase in desktop revenue</a>.
The installed base grew 23% year-over-year to 3,504 devices, with 219 handheld devices and 32 desktop devices placed during the fourth quarter. In 2024, Desktop revenue increased 10% to $13.2 million.
Guidance: 908 Devices expects 2025 revenues of $53 million—$55 million, up 11%—15%, excluding $1 million in revenue in the first quarter before divestiture. The company expects further acceleration above 20% in 2026.
The company now expects to achieve Adjusted EBITDA positivity by Q4 2025 and cash flow positivity in 2026, driven by improved gross margins, which are projected to reach the mid-to-high 50% range in 2025, with further expansion anticipated in 2026 following manufacturing consolidation.
Additionally, the divestiture streamlines operations, reducing headcount by approximately 33% and eliminating $20 million in annual operating losses.
William Blair writes, &#8220;We largely view the company&#8217;s divestiture of its desktop portfolio as a positive from an operational standpoint&#8230;&#8221;
Analyst Matt Larew says Repligen was already establishing a leadership position with products like KrosFlo, and the 908 portfolio will strengthen that position.
As more companies adopt continuous bioprocessing and advanced technologies become more widely used, demand for real-time and in-line analytics tools is expected to grow faster than the overall market. This acquisition aligns with Repligen&#8217;s strategy of acquiring promising technologies early at a reasonable cost while maintaining strong profit margins. It should also ease recent concerns about the types of assets Repligen is pursuing.
The analyst maintains an Outperform rating for <a target="_blank" href="https://www.benzinga.com/quote/RGEN/analyst-ratings" rel="noreferrer noopener">Repligen</a> and <a target="_blank" href="https://www.benzinga.com/quote/MASS/analyst-ratings" rel="noreferrer noopener">908 Devices</a>.
Price Action: MASS stock is up 71.7% at $3.40 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44115724/uber-and-waymo-introduce-self-driving-cars-in-austin-heres-how-it-works" target="_blank" rel="noreferrer noopener">Uber And Waymo Introduce Autonomous Rides In Austin: Here&#8217;s How It Works</a></li>
</ul>

Analyst Color

Large Cap

Health Care

Movers

Trading Ideas

General

MASS

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

Products acquired from 908 Devices include MAVERICK and MAVEN for real-time monitoring and control of critical bioprocess parameters; REBEL, an at-line cell culture media analyzer; and ZipChip, a high-resolution sample separations device used in the characterization of product quality attributes.

Repligen Purchases 908 Devices' Desktop Portfolio Of Four Devices For Bioprocessing Process Analytical Technology Applications For $70M Cash

RBC Capital analyst Conor McNamara maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Outperform and raises the price target from $203 to $205.

RBC Capital Maintains Outperform on Repligen, Raises Price Target to $205

JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Overweight and raises the price target from $190 to $200.

JP Morgan Maintains Overweight on Repligen, Raises Price Target to $200

In the latest quarter, 4 analysts provided ratings for Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Repligen, revealing an average target of $173.75, a high estimate of $180.00, and a low estimate of $165.00. A decline of 10.9% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1740146428_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Repligen is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Hold</td>
<td>$165.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Repligen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Repligen compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Repligen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Repligen's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RGEN/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Repligen analyst ratings.</a>
<h2>Discovering Repligen: A Closer Look</h2>
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
<h3>Key Indicators: Repligen's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Repligen's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 9.69%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Repligen's net margin is impressive, surpassing industry averages. With a net margin of -0.42%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Repligen's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.03%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Repligen's ROA stands out, surpassing industry averages. With an impressive ROA of -0.02%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.33.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Repligen In The Eyes Of 4 Experts

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Buy and maintains $180 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Repligen, Maintains $180 Price Target

Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Hold and raises the price target from $165 to $170.

Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $170

Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>)&nbsp;released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">but beating the consensus of 41 cents</a>.
The bioprocessing technology reported sales of $167.55 million, slightly up from $166.6 million a year ago, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43844804/repligen-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">consensus of $167.67 million</a>.
Olivier Loeillot, President and Chief Executive Officer of Repligen, said, "During the fourth quarter, we were very encouraged by the continued momentum across our portfolio. Total revenue in the fourth quarter grew 13%, excluding COVID-19, overcoming two points of currency headwind. Total orders outpaced sales by 6%, driven by our Filtration and Analytics franchises&#8230;While we continue to monitor China and emerging biotech,&nbsp;the overall bioprocessing market is returning to growth. Our order momentum during the second half gives us confidence that we can achieve our 2025 guidance."
Guidance:&nbsp;Repligen expects 2025 sales of $685 million—$710 million, with organic growth of 9.5%—13.5% and non-COVID revenue growth of 10%—14% compared to the consensus of $694.86 million.
The company expects adjusted EPS of $1.67—$1.76 compared to the consensus of $1.73.
William Blair says Repligen's Q4 results and 2025 outlook confirm that the bioprocessing industry is recovering strongly, with growth expected to return to normal levels next year.
Repligen's guidance reflects strong quarterly momentum, signaling a market recovery.
Compared to peers like Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) and Avantor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NASDAQ">AVTR</a>), which project mid-to-high single-digit growth in bioprocessing, Repligen's outlook highlights its strong product portfolio and customer positioning that have driven consistent above-market growth.
Since Repligen focuses solely on bioprocessing and has minimal exposure to risks in NIH-funded research, academia, or China, analyst Matt Larew believes its guidance is more predictable than competitors with broader market and geographic exposure.
Price Action: RGEN stock is up 8.16% at $163.03 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43853635/hf-sinclair-reports-mixed-q4-results-with-weak-earning-weak-refining-margins-drive-93-drop-in-adjusted-ebitda" target="_blank" rel="noreferrer noopener">HF Sinclair Reports Mixed Q4 Results, Weak Refining Margins Drive 93% Drop In Adjusted EBITDA</a></li>
</ul>
Image via Repligen

Earnings

Guidance

AVTR

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Repligen shares are trading higher after the company reported better-than-expected Q4 financial results

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6">Reconciliation of Earnings Per Share (GAAP) Guidance to Adjusted Earnings Per Share (Non-GAAP) Guidance</td>
</tr>
<tr>
<td colspan="6">Year ending December 31, 2025</td>
</tr>
<tr>
<td colspan="3">Low End</td>
<td colspan="3">High End</td>
</tr>
<tr>
<td colspan="2">GUIDANCE ON EARNINGS PER SHARE (GAAP) - DILUTED</td>
<td>$</td>
<td>0.90</td>
<td>$</td>
<td>0.99</td>
</tr>
<tr>
<td colspan="2">ADJUSTMENTS TO GUIDANCE ON EARNINGS PER SHARE (GAAP) - DILUTED:</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Acquisition and integration costs</td>
<td>0.05</td>
<td>0.05</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Restructuring activities and other related charges</td>
<td>0.04</td>
<td>0.04</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Anticipated pre-tax amortization of acquisition-related intangible assets</td>
<td>0.62</td>
<td>0.62</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Non-cash interest expense</td>
<td>0.25</td>
<td>0.25</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Amortization of debt issuance costs</td>
<td>0.03</td>
<td>0.03</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Tax effect of non-GAAP charges</td>
<td>(0.21</td>
<td>)</td>
<td>(0.21</td>
<td>)</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Guidance rounding adjustment</td>
<td>—</td>
<td>—</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">GUIDANCE ON ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED</td>
<td>$</td>
<td>1.67</td>
<td>$</td>
<td>1.76</td>
</tr>
</tbody>
</table>
</figure>

Repligen Sees FY2025 GAAP EPS $0.90-$0.99 Vs, $0.81 Estimate

Repligen Sees FY2025 Adj EPS $1.67-$1.76 vs $1.73 Estimate

Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.41 by 7.32 percent. This is a 8.33 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $167.55 million which missed the analyst consensus estimate of $167.67 million by 0.07 percent. This is a 0.56 percent increase over sales of $166.62 million the same period last year.

Earnings Beats

Earnings Misses

Repligen Q4 2024 Adj EPS $0.44 Beats $0.41 Estimate, Sales $167.55M Miss $167.67M Estimate

ACCO

AKAM

ALIT

ALRM

ARDX

ATHM

AXTI

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BJRI

BKNG

BLDR

CARG

CCRD

CDRO

CELH

CENX

CERS

CGAU

COKE

COLD

CPRT

CRAI

CSTM

DAVA

DBRG

DGICA

DGICB

DINO

DVAX

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GKOS

GLOB

GLPI

GMED

GRAL

INDI

INDV

INOD

INSM

IRTC

ITGR

Earnings Scheduled For February 20, 2025

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Buy and lowers the price target from $240 to $180.

HC Wainwright & Co. Maintains Buy on Repligen, Lowers Price Target to $180

Repligen Announced The Commercial Launch Of Its CTech SoloVPE PLUS System For At-line Ultraviolet-visible Concentration Measurement In Complex Biological Production Workflows, From Process Development Scale Through cGMP Manufacturing

Canaccord Genuity analyst Kyle Mikson initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Hold rating and announces Price Target of $165.

Canaccord Genuity Initiates Coverage On Repligen with Hold Rating, Announces Price Target of $165

Wolfe Research analyst Doug Schenkel initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Peer Perform rating.

Wolfe Research Initiates Coverage On Repligen with Peer Perform Rating

Press Releases

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Small Cap

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

Repligen Launches the CTech™ SoloVPE® PLUS System

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Repligen Reports Fourth Quarter and Full Year 2024 Financial Results

Contracts

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

Management

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Repligen to Report First Quarter 2025 Financial Results

BLFS

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Repligen

Vendite allo scoperto

Repligen (NASDAQ:RGEN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO